DANCR-mediated MicroRNA-665 Regulates Proliferation and Metastasis of Cervical Cancer Through the ERK/SMAD Pathway
Overview
Affiliations
Emerging evidence has indicated that microRNAs (miRNAs) play an important role in cervical cancer (CC). However, the role of miRNA (miR)-665 in cervical cancer remains unclear. The aim of the present study was to investigate the potential functions of miR-665 in CC and to identify the underlying mechanisms of action. Herein, we show that miR-665 was downregulated in CC tissues and cell lines, which is negatively correlated with tumor size, distant metastasis, advanced TNM stage and poor prognosis. Functionally, miR-665 inhibited cell proliferation, migration and invasion and resistance of cisplatin for CC cells, as well as tumor growth. We validated that transforming growth factor beta receptor 1 (TGFBR1) was a direct target of miR-665 and mediated the ERK/SMAD pathway. In addition, we identified miR-665 as the competing endogenous RNA for long noncoding (lnc)-DANCR. These observations suggested that lnc-DANCR-mediated miR-665 downregulation regulates the malignant phenotype of CC cells by targeting TGFBR1 through the ERK/SMAD pathway, which may present a pathway for novel therapeutic stratagems for CC therapy.
Hosseini Farzad S, Lashkarboloki M, Mowla S, Soltani B Mol Biol Rep. 2024; 52(1):36.
PMID: 39643825 DOI: 10.1007/s11033-024-10128-0.
Gao J, Zhang X, Xu A, Li W, Gao H Hereditas. 2024; 161(1):34.
PMID: 39285452 PMC: 11403863. DOI: 10.1186/s41065-024-00336-w.
New evidence for a role of DANCR in cancers: a comprehensive review.
Yuan R, Xu Z, Zhang S, Cao X, Dai A, Song L J Transl Med. 2024; 22(1):569.
PMID: 38877534 PMC: 11177382. DOI: 10.1186/s12967-024-05246-z.
HOXB2 promotes cisplatin resistance by upregulating lncRNA DANCR in ovarian cancer.
Li X, Zheng Z, Zhou W, Huang H, Zhou Y, Xu Q J Ovarian Res. 2024; 17(1):124.
PMID: 38851728 PMC: 11161928. DOI: 10.1186/s13048-024-01424-1.
Interplay between LncRNA/miRNA and TGF-β Signaling in the Tumorigenesis of Gynecological Cancer.
Safavi P, Moghadam K, Haghighi Z, Ferns G, Rahmani F Curr Pharm Des. 2024; 30(5):352-361.
PMID: 38303530 DOI: 10.2174/0113816128284380240123071409.